Physician profile
Partha S Nandi
NPI 1184605206
$376,542.08
in general payments reported to CMS, 2019-2025
24 companies · $140K in 2025
The $140K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.00 · 2021: $1,665 · 2022: $11K · 2023: $1,170 · 2024: $222K · 2025: $140K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $269K · Travel and Lodging: $41K · Consulting Fee: $28K · Honoraria: $17K · Food and Beverage: $9,079 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $269,057.86 |
| Travel and Lodging | $40,690.39 |
| Consulting Fee | $27,868.75 |
| Honoraria | $16,640.00 |
| Food and Beverage | $9,079.31 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $179,279.20 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $152,453.57 | 2024-2025 | Voquezna |
| Medtronic, INC. | $19,822.43 | 2022-2024 | Pillcam, Interstim |
| Madrigal Pharmaceuticals | $8,673.36 | 2024-2025 | Rezdiffra |
| Eli Lilly and Company | $7,092.31 | 2024 | Omvoh |
| Abbvie INC. | $6,412.69 | 2023-2025 | |
| Redhill Biopharma INC. | $1,665.00 | 2021 | |
| Pfizer INC. | $221.00 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.01 | 2023-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $176.41 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.32 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Merck Sharp & Dohme LLC | $64.45 | 2023-2025 | Dificid |
| Genentech, INC. | $38.00 | 2019 | |
| Amgen INC. | $37.83 | 2023-2025 | Amjevita, Avsola |
| Ardelyx, INC. | $36.42 | 2023 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mauna Kea Technologies, INC. | $31.70 | 2024 | |
| Capsovision, INC. | $31.00 | 2023 | Capsocam Plus |
| Enterra Medical, INC. | $29.53 | 2024 | |
| Ferring Pharmaceuticals INC. | $27.96 | 2024 | Rebyota |
| Celgene Corporation | $24.03 | 2024 | Zeposia |
| Astrazeneca Pharmaceuticals Lp | $19.36 | 2024 | Farxiga |
| Sandoz INC. | $19.28 | 2024 | |
| Gilead Sciences, INC. | $18.90 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.32 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Partha Nandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.